...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants
【24h】

Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants

机译：低分子量肝素，华法林和直口腔抗凝剂患者静脉血栓栓塞治疗静脉血栓栓塞治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Direct oral anticoagulants (DOACs) are not recommended for venous thromboembolism (VTE) treatment in patients with cancer because their safety and efficacy have not been compared to low molecular weight heparin (LMWH) in large trials. Routine anti-Xa monitoring in cancer patients on LMWH is also not recommended due to limited data correlating anti-Xa levels and outcomes. Objective Compare the safety and efficacy of DOACs to LMWH and warfarin and assess the relationship of anti-Xa monitoring and outcomes in patients with cancer taking LMWH in an urban university setting. Methods This retrospective, cohort study analyzed the recurrence of VTE and number of bleeding events in patients with cancer. Results There were 131 patients included in the analysis. There was no difference seen in the rate of recurrent VTEs between the LMWH, warfarin and DOAC groups (9.3%, 5.9%, 9.1%, p = 0.89). There was also no difference in the rate of bleeding between groups (10.5%, 14.7%, 9.1%, p = 0.576). There was an increased rate of mortality seen in the LMWH group (26.7% vs. 2.9% vs. 18.2%, p = 0.006). There was no difference seen in recurrent VTE (10.3% vs. 8.5%, p = 0.53) or bleeding (10.3% vs. 10.7%, p = 0.661) between the monitored and unmonitored LMWH patients. Conclusion
机译：背景技术癌症患者的静脉血栓栓塞（VTE）治疗不建议直接口服抗凝剂（DOAC），因为它们的安全性和功效尚未与大型试验中的低分子量肝素（LMWH）进行比较。由于抗XA水平和结果有限，也不推荐常规抗XA监测LMWH的癌症患者。目的比较Doacs对LMWH和Warfarin的安全性和疗效，并评估癌症患者抗XA监测和结果的关系，在城市大学环境中服用LMWH。方法对癌症患者的VTE和出血事件的复发分析了癌症的复发。结果分析中有131名患者。 LMWH，Warfarin和DoAC组之间的复发性VTE率没有差异（9.3％，5.9％，9.1％，P = 0.89）。群体之间出血的速率也没有差异（10.5％，14.7％，9.1％，P = 0.576）。在LMWH组中存在的死亡率增加（26.7％与2.9％对18.2％，p = 0.006）。在监测和未监测的LMWH患者之间，复发性VTE中没有看到的（10.3％对8.5％，P = 0.53）或出血（10.3％vs.1.0.7％，p = 0.661）。结论

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号